AbbVie have paid $200 million to get Nimble Therapeutics investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis.

Quote:

---

IL-23 is a cytokine that activates Th17 cells, promoting an inflammatory response that contributes to tissue damage and organ dysfunction.

IL-23R is a receptor involved in the IL-23/IL-17 immune pathway, crucial in the pathogenesis of psoriasis and IBD. Upregulation of IL-23R expression is associated with increased susceptibility to IL-23 signaling, amplifying inflammation and immune responses in psoriasis and inflammatory bowel diseases (IBD), and underpinning the significant clinical efficacy of IL-23 blocking antibodies in these diseases. IL-23R antagonists block the interaction between IL-23 and its receptor, inhibiting the Th17 inflammatory pathway, cytokine production and IL23R upregulation, alleviating inflammation.

We are developing an innovative oral IL-23R antagonist by combining potent activity with gut stability and extended half-life. This medication will offer a more effective oral therapy option for patients seeking less invasive, more effective and convenient treatments.

I had a dermatology appointment yesterday.  I'm seeing this doctor annually now that I've learned how to manage my psoriasis and am doing okay.  I'm just so grateful to her.  She is thorough and smart and committed to relieving suffering.  This person could have risen to the top in any field, but she chose skin and her dedication to years of medical education and the care she has provided to me have helped me (along with many others, of course).  I am better.  I guess I just want to acknowledge this.

But as I get older, I think there's gonna be annual biopsies for skin cancer, too.  I have two sore spots now, covered in bandages from yesterday's punch biopsies.  

Maybe in the long run, having psoriasis lowers my chances of dying from skin cancer since it will be checked for regularly.  I might not have ever seen a dermatologist if I didn't get psoriasis.

I have had Guttate Psoriasis for almost three years now, after a mild case of COVID (That's a story for another day}.  Guttate typically resolves fairly quickly, mine did not.  I was on Humira for 7 months and got moderate relief.  The Humira quit working for me.  I am now trying to get on Tremfya.  I have had Plaque psoriasis since I was 12 years old, and that is largely in remission.

This article suggests there is a link between ultraprocessed foods and psoriasis.

Quote:

---

Methods:
We performed a cross-sectional study using data from the Nutri-Net-Santé cohort study between November 29, 2021, and June 6, 2022. The French Institute for Health and Medical Research Institutional Review Board approved this study. All participants provided electronic informed consent. We followed the STROBE reporting guideline.

A validated self-diagnosis questionnaire was used to classify participants (aged ≥15 years) by their psoriasis status (never-had, nonactive, or active) at the time of the survey. For each participant, UPF intake in grams per day was extracted and divided into 3 tertiles, ranging from minimum (tertile 1) to maximum (tertile 3) intake. Associations were assessed using multinomial logistic regression models adjusted for age, sex, educational level, smoking status, physical activity, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), alcohol intake, and comorbidities (depression, cancer, cardiovascular disease [CVD], diabetes, hypertriglyceridemia, inflammatory bowel disease [IBD], inflammatory rheumatism), and number of dietary records completed.

Two-sided P < .05 indicated statistical significance. Data analysis was performed with SAS, version 9.4 (SAS Institute Inc).

Results:
A total of 18 528 participants (median [IQR] age, 62 [49-70] years; 13 755 females [74%], 4773 males [26%]) were included, of whom 1825 (10%) had psoriasis with 803 cases being active (4%). The active psoriasis group had a lower proportion of females (68% [546] vs 74% [12 441] and 75% [768]) and a higher proportion of individuals with BMI over 30 (16% [129] vs 9% [1524] and 11% [115]) than the never-had and nonactive groups. High-intensity physical activity was less frequent in the active and nonactive groups than in the never-had group (308 [38%] and 396 [39%] vs 6943 [42%]). Comorbidities that were more frequent in the active vs never-had group were CVD (58 [7%] vs 773 [5%]), diabetes (45 [6%] vs 623 [4%]), IBD (13 [2%] vs 151 [1%]), and inflammatory rheumatism (69 [9%] vs 455 [3%]).

In unadjusted analysis, UPF intake differed between active and never-had groups (tertile 3 odds ratio [OR], 1.52; 95% CI, 1.28-1.81; P for trend < .001). After adjustments, high UPF intake was more likely in the active group than lower UPF intake (tertile 3 adjusted OR, 1.36; 95% CI, 1.14-1.63). Sensitivity analyses showed no association for participants with a psoriasis diagnosis validated by a dermatologist.

Discussion:
Results of this study showed an association between high UPF intake and active psoriasis status. After adjustments for age, BMI, alcohol intake, and comorbidities, the results remained significant, suggesting that UPF intake has a proinflammatory action separate from high BMI.4

Study limitations included the study population differing from the French general population (notably with healthier dietary habits5), which might have led to an underestimation of association levels detected. Additionally, psoriasis cases were self-reported, possibly leading to misclassification. However, self-declaration of psoriasis had excellent sensitivity (82.2%) and specificity (98.6%) and receiver operating characteristic curve (0.90; 95% CI, 0.87-0.94) in a cross-sectional diagnostic study of 89 patients with psoriasis.6 Our models also were adjusted for known and potential confounding factors, minimizing confounding bias. However, residual bias could persist. Furthermore, the cross-sectional, observational study design prevented us from ascertaining whether elevated UPF intake precedes or is a consequence of psoriasis flare-ups.

High UPF intake was associated with active psoriasis status. More large-scale studies are needed to investigate the role of UPF intake in psoriasis onset.

Glad to be here.  I hope that I can share my 51 years of experience as someone living with Psoriasis.   As my conditioned has worsened, I hope to access the knowledge and experiences you all have.

Hello, fellow flakeys. Long-time sufferer here. Psoriasis and psoriatic arthritis has definitely made a dent in my life. I'm finally in somewhat of a remission, but I tend to develop a tolerance to meds over time. At least with all of the new meds they keep coming up with, it leaves me options for finding new ones.

I used to be married, lived on a farm, and took care of kids, cats, dogs, horses, sheep, rabbits, and a few chickens while working as a kennel attendant in a veterinarian's office. Now I'm divorced, unemployed, on disability, and live in a tiny house with a roommate and her kid. 

I do have two dogs, but I lost my two cats in the last couple of years and haven't found new ones that need homes yet.

I'm finally back to my favorite hobby (cross-stitch) after a bad flare starting last year. The Cosentyx has done wonders, but I'll never be as active as I once was. I've learned to slow down, but it hasn't been easy. 

I hope everyone is doing well and finding what treatment works best for them. Take care and I'll see you around.

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis.

Quote:

---

We have developed a dry patch, which contains active ingredients for treatment of psoriasis, and which reduces the frequency of use to once a day. It has the potential to make treatment more comfortable for psoriasis patients.

The patch is designed to contain two active ingredients at once and release them onto the skin at different rates.

The two ingredients are released in a controlled manner and at different rates, as they serve different functions: Salicylic acid is released immediately to remove the dead cells that have accumulated on the skin, while hydrocortisone decreases inflammation of the skin – a process that takes more time.

We have tested the prototype on pig skin and human skin cells and compared the results to the creams and ointments available at pharmacies, and our studies show that the patch is just as effective as standard treatments.

The researchers used electrospinning to produce the patch – a method where high voltage is applied to a polymer solution to produce synthetic nanofibers. The fibres are then used to make a fibre mat that may be attached to the skin like a plaster.

The researchers are still working on the patch. More research, product development and clinical trials are needed before the method is ready for use.

Hey everyone,

It's been a very long while. Sorry I have been away. I am struggling for a while with thing going on in my life. Lost my brother in 2021 and lost my dad in 2023. My plaque psoriasis are flaring up. This past July I was diagnosed with psoriatic arthritis and fibromyalgia. Currently onTriamcinolone ointment and methotrexate.
Sarah

Does psoriasis effect the clothes you wear ?

Members and guests can vote in the poll above, and our members are welcome to post in this thread too if they wish.

More Psoriasis Club Polls

Management of moderate to severe psoriasis with Kyntheum / Siliq (brodalumab) real world evidence from the LIBERO study.

Quote:

---

Background:
Brodalumab, a fully human monoclonal immunoglobulin IgG2 antibody that binds the human interleukin 17 receptor subunit A, is available for the treatment of moderate-to-severe plaque psoriasis in Europe since September 2017, but so far there are only a few studies on its use in real-world conditions.

Objectives:
To assess the management of moderate-to-severe psoriasis with brodalumab 210 mg in daily practice after 12 and 52 weeks (W). In addition, patient profiles and treatment pathways are described.

Methods:
LIBERO is a prospective, multicenter, non-interventional study including adult patients with plaque psoriasis treated with brodalumab 210 mg.

Results:
In total, 638 patients (65% male, mean age: 49.3 ± 14.4 years) from 148 sites in Germany were enrolled. The majority suffered from severe (51.1%) or very severe (13.1%) psoriasis according to physician global assessment (PGA0-5). When starting with brodalumab, 58.5% were biologic naïve and 41.5% were previously treated with another biologic, mainly adalimumab (18.5%) and secukinumab (17.9%). About 74.0% of patients met the primary endpoint of an absolute PASI ≤3 at ~W12 (n = 618, LOCF). The mean PASI was reduced significantly as of ~W2 from 17.2 (±11.7) to 9.7 (±8.8) and improved further to 3.3 (±6.3) at ~W12 (p < 0.001). At ~W52 85.5% of patients reached a PGA0/1-response (primary endpoint) and 54.1% patients were assessed as completely clear (PGA0) (both n = 399, as observed). Effectiveness of brodalumab was confirmed in relevant subgroup analysis by previous treatment regimen. Most frequently reported adverse events were nasopharyngitis (4.6%), psoriasis (4.6%) and arthralgia (4.1%), new safety signals were not detected.

Conclusions:
This representative, non-interventional study confirms the short- and long-term effectiveness and safety profile of brodalumab in the management of psoriasis in daily practice as well as in relevant treatment pathways.

Not aimed specifically at psoriasis, but phase 1 was on patients with psoriasis. In early 2025, Calluna plans to advance CAL101 into Phase 2 studies in fibrotic and fibro-inflammatory indications.

Quote:

---

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate. The study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile for the mAb.

CAL101 is a first-in-class mAb that targets S100A4, a damage-associated molecular pattern (DAMP) protein implicated in serious and life-threatening diseases, such as idiopathic pulmonary fibrosis and systemic sclerosis. Preclinical studies have demonstrated the ability of CAL101 to prevent and treat fibrosis and modify the disease-specific activation of fibroblasts – the key effector cells driving progression of fibrosis.

Jonas Hallén M.D., Ph.D., Co-Founder and Chief Medical Officer of Calluna Pharma, commented: “We are encouraged by the findings from the Phase 1 study. These results are an important step forward in the development of our lead asset, CAL101, particularly for fibrotic and fibro-inflammatory diseases where there remains a critical need for innovative therapeutic options. We are excited as we now move into the next phase of clinical development.”

The first-in-human, randomized, double-blind, placebo-controlled Phase 1 study in 57 subjects was designed to evaluate safety, tolerability, immunogenicity and PK, and was led by Professor Dave Singh at the Medicines Evaluation Unit in Manchester, UK. The study tested single ascending doses of CAL101 in healthy volunteers and multiple ascending doses in patients with mild to moderate chronic plaque psoriasis.

Summary of key CAL101 Phase 1 study results:

• CAL101 demonstrated a favorable safety profile and was well tolerated with no Serious Adverse Events across all doses tested.
  
• Adverse Events were all mild to moderate and balanced between CAL101 and placebo.
  
• CAL101 demonstrated a favorable PK profile with dose-dependent increases in exposure, supporting once monthly dosing.
  
• In participants with anti-drug antibodies, titers were very low and with no impact on PK and safety.
  
• Target engagement data supports complete target coverage at clinically relevant doses.
  

Currently you need two shots at 160mg each, but soon in the USA and EU you will be able to get one shot at 320mg

Quote:

---

UCB  today announced that the U.S. Food and Drug Administration (FDA) has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx).

These new device presentations add to the currently available 1 mL administration options, each containing 160 mg of bimekizumab-bkzx, and mean that patients requiring a 320 mg dose of bimekizumab-bkzx will have options for single-injection administration.

“Our goal with these single-injection regimens is to strengthen and expand administration options, increase convenience and enhance the individual patient experience,” said Emmanuel Caeymaex, Executive Vice President, Head of Patient Impact, Chief Commercial Officer, UCB. “With the new device presentations, people with moderate-to-severe plaque psoriasis who receive a bimekizumab-bkzx maintenance dose of 320 mg will have the option of a single-injection every eight weeks.”

The approval of the 320 mg device presentations is supported by data from studies evaluating the bioequivalence of bimekizumab-bkzx 320 mg given as one 2 mL subcutaneous injection, and bimekizumab-bkzx 320 mg given as two 1 mL subcutaneous injections, in healthy study participants. This is the second worldwide approval for the 320 mg single-injection administration options for bimekizumab-bkzx, following approval by the European Commission in August 2024.

These new device presentations will be available in the U.S. in Q1 2025.

Do any of you have/had any comorbidities ? I've added the most common to the poll above, if you have others please let me know.

Members and guests can vote in the poll above, and our members are welcome to post in this thread too if they wish.

More Psoriasis Club Polls

UCB today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing Bimzelx (bimekizumab), an IL-17A and IL-17F inhibitor, with Skyrizi (risankizumab), an IL-23 inhibitor, in the treatment of adults with active psoriatic arthritis (PsA). BE BOLD is the first head-to-head study in PsA evaluating the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor. 

Quote:

---

This is the first Phase 3b head-to-head study in psoriatic arthritis to utilize the primary endpoint of ACR50 at Week 16. This robust assessment is set to provide a meaningful comparison of bimekizumab vs. risankizumab on inflamed joints, one of the areas of most concern for many people living with psoriatic arthritis. We look forward to the results and the implications for future clinical practice.

In moderate to severe plaque psoriasis UCB has conducted three head-to-head Phase 3/3b studies with bimekizumab versus commonly used biologics, and results from these studies showed that bimekizumab was superior to secukinumab, ustekinumab and adalimumab,

BE BOLD represents the fourth head-to-head study in the bimekizumab clinical trial program, the first to be conducted in psoriatic arthritis, and the first versus an IL-23 inhibitor. This study underscores our confidence in the potential of bimekizumab for people living with psoriatic disease. We look forward to communicating the top-line results in 2026.

BE BOLD is a multicentre, randomized, double-blind, risankizumab controlled, parallel-group study designed to evaluate the efficacy and safety of bimekizumab in adult study participants (n=~550) with active psoriatic arthritis. The study population will include adults with active psoriatic arthritis who are biologic treatment naïve or who had previous exposure to one tumour necrosis factor-inhibitor (TNFi) with an inadequate or intolerant response. The primary endpoint will assess American College of Rheumatology 50 (ACR50, i.e., 50 percent or greater improvement in the signs and symptoms of psoriatic arthritis) at Week 16. Key ranked secondary endpoints include minimal disease activity at Week 16, and the composite endpoint, ACR50 and PASI100 (complete skin clearance) at Week 16.

Well a very brief summary of where I am at first. Started on Methotrexate worked well for a number of years until I was taken off it due to poor liver score which is now back to a 0-1. I then went on to Acitretin which nearly killed me! Severe reaction did something to my blood counts and I got called to come off it straight away and stay at home for 2 weeks so I didn't get so much as a cold. Then Apremilast and which didn't work and my consultant had me taking Apremilast with Skilarence. These didn't work either. Lastly for the past 2 years I have been on Cislosporine. 

Now I have to come off Ciclosporine as you can only be on it for 2 years.

Now, my consultant prescribed me Skilarence again and I declined as it didn't work and he said he had not prescribed it and he had no record of it! Great, not keeping proper medical records.

He tried again to get me to go on it but I have insisted on a referral but he has stated I cannot be referred to the biologicals team until I have a PASI. However, I am now not on any medication and I know that in the coming months my psoriasis will flare up again. His secretary stated NICE guidlines which I have read and none of them prevent hinm referring me, what the guidelines are is a PASI of 10 and a DLQI of 10 to be prescribed biologicals.

I will easily hit these when my current medication wears off and not looking forward to a flare up. I am tempted to push to get the referal as there is a wait after he refers me anyway, he can do it immediately and I am in the queue and my take is that I have a condition that will deteriorate and now I am in a position where they are doing nothing about it.

Interestingly I know its about cost and I asked to go back on methotrexate as my liver scores indicate there is no damage, the NICE guidelines he states suggest methotrexate as a first line of defence followed by other treatments.

Today I am at a loss as to escalate via PALs, ask for a second opinion or even go full nuclear and report incorrect records keeping and duty of care.

Any advice greatly appreciated any questions feel free to ask.

Thanks and sorry for the rambling rant.

I've had plaque psoriasis since 1983. In the past year, a rheumatoligist came to believe I have psoriatic arthritis, based on chronic  stiff joint symptoms and xrays showing mild joint space shrinkage. Blood tests to support this were all negative. She also suggested I try Rinvoq and provided a 30 day free trial. I've not taken this drug. Frankly, I'm not sure the pain is bad enough and the side effects for someone my age (over 65) are a bit alarming. I'm curious of what others may have experienced in combating my issues. The score I get on this website is 13 and the psoriasis plaquing bothers me much less than the joint pain.

It is a very long time since I have been here, I kind of lost track of it and searched a few times but didn't manage to find the site but today I have.

So whats new! I was on methotrexate and eventually got taken off it. I was given skilerance that didn't work but my consultant has no record of it so has prescribed it again. I need to get the pharmacy to write to him telling him that I have already tried it! I had acretin that nearly killed me. You know when you have a blood test and within hours your GP and consultant ring you and tell you to stop taking the drug immediately and to go to hospital the next day for tests, I think it was my neutrophils cells had plummeted so I had basically no immune system, something like that anyway. Then I went on cyclosporine which I have just been taken off.

Life is OK learned to cope with psoriasis a long time ago and it has generally been a lot more manageable apart form about 12 months after I was taken off methotrexate. I know I know its a bad drug but worked for me until my liver needed to recover a little.

If I don't end up on the skilerance I will be on biologicals.

Anyway I am glad I found you.

The Health Sciences Authority (HSA) Singapore are advising anyone using Touch Skin by Dermacare Skin Relief Treatment Cream to stop using it immediately.

Quote:

---

The Health Sciences Authority (HSA) is alerting members of the public not to purchase or use “Touch Skin by DermaCare Skin Relief Treatment Cream”. Tests revealed that the cream contained a potent steroid (betamethasone valerate) which should be used under medical supervision. A consumer in her 50s suffered severe skin reactions from the use of the cream.

The consumer had been using the cream for about 8 years for her sensitive facial skin and would experience flare-ups (a sudden worsening of symptoms) whenever she stopped applying the cream. In May 2024, she saw that HSA alerted the public to a similar product found to be adulterated with a steroid, she immediately stopped the use of the cream, two days after stopping use she developed red, sensitive and itchy skin on her face and consulted a doctor. The doctor found her skin to be severely inflamed, sensitive to sunlight, and thinned-out with telangiectasia (spider veins) and reported the adverse event to HSA.

Consumers should be alert to the dangers of purchasing skin creams from dubious, unfamiliar or online sources. From 2022 to July 2024, HSA had detected an increased number of creams marketed for skin conditions (e.g., rash, eczema and psoriasis) adulterated with steroids and other potent medicinal ingredients.

The majority of the creams were used in young children. As young children are more susceptible to the effects of adulterants such as steroids, they suffered serious adverse effects from the use of these creams. The creams were sold on websites, e-commerce platforms, social media platforms, and in one case, by a peddler in a makeshift stall.

Adulterated products are often manufactured under poor conditions with no quality control, and different batches of the same product may contain variable amounts of ingredients and/or different types of adulterants.

All sellers and suppliers must stop selling these products immediately. HSA will not hesitate to take stern enforcement actions against anyone who sells and supplies products found to be adulterated with steroids. Sellers and suppliers are liable to prosecution and if convicted, may be imprisoned for up to 3 years and/or fined up to $100,000.

This large-scale Korean cohort study of children provided evidence that higher BMI was linked to an increased risk of developing AA, AD, and psoriasis among children.

Quote:

---

Whether childhood obesity or weight gain leads to the development of pediatric immune-mediated skin diseases remains unclear. We aimed to determine the associations between body mass index or body mass index changes and the development of 3 main immune-mediated skin diseases—alopecia areata, atopic dermatitis (AD), and psoriasis—by analyzing a longitudinal cohort of 2,161,900 Korean children from 2009 to 2020.

The findings indicated that children who were obese had a higher risk of pediatric immune-mediated skin diseases than those with normal weight (P for trend < .01). An increase in body mass index was associated with a higher risk of AD, whereas a decrease in body mass index was correlated with a reduced risk of AD.

Children who gained weight, transitioning from normal to overweight, exhibited a higher AD risk than those who maintained a normal weight (adjusted hazard ratio = 1.15, 95% confidence interval = 1.11–1.20). However, those who shifted from being overweight to achieving a normal weight (adjusted hazard ratio = 0.87, 95% confidence interval = 0.81–0.94) had a lower AD risk than children who were overweight who maintained their weight.

In summary, early childhood obesity may increase the risk of pediatric immune-mediated skin diseases like psoriasis. Weight gain may increase AD risk, whereas weight loss may lower the risk.

Early results from an ongoing study have found there is a high level of psoriatic arthritis (PsA) amongst patients with psoriasis.

Quote:

---

Early results of an international study examining the risk of arthritis for people with psoriasis have shown a high burden of joint symptoms in 712 patients – 25% of the total studied so far.

The study led by researchers at the Universities of Oxford, University College Dublin and supported by The University of Manchester has recruited almost 3,000 patients so far.

The 25% figure results confirms existing knowledge that up to a third will go on to develop psoriatic arthritis (PsA), which causes joints and tendons to become inflamed and painful.

At the moment there is no way to predict which patients with psoriasis are likely to go on to develop joint problems but this research will help us to design ways to prevent people with psoriasis developing arthritis, by offering potential drug treatments or lifestyle interventions such as exercise or stress management.

We know that some patients with psoriasis will go on to develop psoriatic arthritis. If we could identify which patients are at higher risk for arthritis development, it could mean that in the future, those people could receive preventative treatment.

To date, we have baseline data on a total of 2,841 patients, of which 1761 are from Ireland and 1067 are from the UK.

GPs are not always skilled enough to spot the symptoms and they may manifest themselves in a myriad of different ways. Receiving a diagnosis is in many ways a relief, patients can then plan for the future knowing that they do indeed have an ongoing condition.